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Autologous chondrocyte implantation for the treatment of cartilage lesions:
randomized control trials assessed in a systematic reviewThe systematic review (SR) “Effectiveness of autologous chon-
drocyte implantation in cartilage repair of the knee: a systematic
review of controlled trials”11 highlights how limited and prone to
bias is the evidence on a topic as important and of great commercial
interest as autologous chondrocyte implantation (ACI). The conclu-
sions reached by Vavken et al. are in line with a recently published
SR9. This review, which included also studies comparing ACI vs any
other treatment and also comparisons between different ACI tech-
niques, concluded that the existing published evidence does not
allow conclusions to be drawn regarding the relative effectiveness
of ACI compared to other treatments9.
We would like to further highlight some characteristics of the
included studies, which, to our appreciation, impose further limita-
tion to the magnitude and credibility of the available body of
evidence than those acknowledged by Vavken et al.
Nine studies were included in the SR by Vavken et al. However,
three pairs of the studies were performed by the same authors;
Saris et al.6,7, Knutsen et al.4,5 and Horas et al.2,3 published two
studies each, including the same group of patients. As acknowl-
edged by Vavken et al., the studies by Saris and Knutsen refer to
the assessment of the same patients at different follow-up times.
However, the studies by Horas present results for the same
group of patients and the same follow-up time. According to Horas
et al. response after a letter to the editor that followed their publi-
cation in 20038, “the same patient population formed the basis for
both the German publication (i.e., Horas 20003) and the present
article (i.e., Horas 20032). However, different individual aspects of
the treatment’s results were highlighted, especially in the Discus-
sion sections of the two articles”. It is therefore not surprising
that Horas 2000 was not included as a separate randomized control
trial (RCT) in previously published SRs which also had no language
limit, or at least included German publications1,9,12 and it is also not
included in the upcoming updated version of the Cochrane SR10.
Overall, the SR by Vavken et al. does not include nine studies, but
six studies published in nine papers. The total sample size is not
561 as stated by Vavken et al., but 441.
The SR by Vasiliadis et al. so evaluated additional sources of bias.
The studies were also assessed for baseline differences and selec-
tive reporting. Only two studies2,5 were found free of these two
additional sources of bias. In the remaining items (randomization,
allocation concealment, attrition, blinding) there are some differ-
ences in the judgments between Vavken et al. and Vasiliadis et al.
This may be partly attributed to the fact that Vasiliadis et al. con-
tacted the corresponding author of each when additional informa-
tion was required.
Despite these small differences in methodology, the conclusions
of the two reviews are in line. The similarity in ﬁndings in these two1063-4584/$ – see front matter  2010 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2010.05.023studies undertaken by two independent teams highlights the
urgency to design large randomized trials of low risk of bias with
adequately long follow-up to inform about the best treatment avail-
able for the full thickness cartilage lesions.
Author contributions
HV substantially contributed to the conception and design,
acquisition of data, analysis and interpretation of results and
writing the letter.
GS substantially contributed to the conception and design, inter-
pretation of results and writing the letter.
Conﬂict of interest
None.
Acknowledgments
Other contributors, acknowledgment of funding sources and
statement of role of funding source in publication, etc.: none.
References
1. Clar C, Cummins E, McIntyre L, Thomas S, Lamb J, Bain L. Clinical
and cost-effectiveness of autologous chondrocyte implantation
for cartilage defects in knee joints: systematic review and
economic evaluation. Health Technol Assess 2005;9:iii–x, 1.
2. Horas U, Pelinkovic D, Herr G, Aigner T, Schnettler R. Autologous
chondrocyte implantation and osteochondral cylinder trans-
plantation in cartilage repair of the knee joint. A prospective,
comparative trial. J Bone Joint Surg Am 2003;85-A:185–92.
3. Horas U, Schnettler R, Pelinkovic D, Herr G, Aigner T. Osteo-
chondral transplantation versus autogenous chondrocyte
transplantation. A prospective comparative clinical study.
Chirurgia 2000;71:1090–7.
4. Knutsen G, Drogset JO, Engebretsen L, Grontvedt T, Isaksen V,
Ludvigsen TC. A randomized trial comparing autologous chon-
drocyte implantation with microfracture. Findings at ﬁve
years. J Bone Joint Surg Am 2007;89:2105–12.
5. Knutsen G, Engebretsen L, Ludvigsen TC, Drogset JO,
Grontvedt T, Solheim E. Autologous chondrocyte implantation
compared with microfracture in the knee. A randomized trial.
J Bone Joint Surg Am 2004;86-A:455–64.
6. Saris DB, Vanlauwe J, Victor J, Almqvist KF, Verdonk R,
Bellemans J, et al. Treatment of symptomatic cartilage defects
of the knee: characterized chondrocyte implantation results
in better clinical outcome at 36 months in a randomized trialblished by Elsevier Ltd. All rights reserved.
Letter to the Editor / Osteoarthritis and Cartilage 18 (2010) 1358–1359 1359compared to microfracture. Am J Sports Med 2009;37
(Suppl 1):10S–19S.
7. Saris DB, Vanlauwe J, Victor J, Haspl M, Bohnsack M, Fortems Y,
et al. Characterized chondrocyte implantation results in better
structural repair when treating symptomatic cartilage defects
of the knee in a randomized controlled trial versus microfrac-
ture. Am J Sports Med 2008;36:235–46.
8. Smith GD, Richardson JB, Brittberg M, Erggelet C, Verdonk R,
Knutsen G. Autologous chondrocyte implantation and osteo-
chondral cylinder transplantation in cartilage repair of the
knee joint. J Bone Joint Surg Am 2003;85-A:2487–8.
9. Vasiliadis HS, Wasiak J, Salanti G. Autologous chondrocyte
implantation for the treatment of cartilage lesions of the
knee: a systematic review of randomized studies. Knee Surg
Sports Traumatol Arthrosc 2010. Feb 2. [Epub ahead of print]
(PMID: 20127071).
10. Vasiliadis HS, Wasiak J. Autologous chondrocyte implantation
for full thicknessarticular cartilagedefectsof theknee. Cochrane
Database Syst Rev; CD003323 (Submitted for publication).
11. Vavken P, Samartzis D. Effectiveness of autologous chondro-
cyte implantation in cartilage repair of the knee: a systematicreview of controlled trials. Osteoarthritis Cartilage 2010;18(6):
857–63.
12. Wasiak J, Clar C, Villanueva E. Autologous cartilage implanta-
tion for full thickness articular cartilage defects of the knee.
Cochrane Database Syst Rev 2006;3:CD003323.H.S. Vasiliadisyz*, G. Salantix
yOrthopaedic Sports Medicine Center, Department of Orthopaedics,
School of Medicine, University of Ioannina, Greece
zMolecular Cell Biology and Regenerative Medicine,
Sahlgrenska University Hospital, Gothenburg University, Sweden
xClinical and Molecular Epidemiology Unit, Department of Hygiene
and Epidemiology, University of Ioannina School of Medicine,
Ioannina, Greece
* Address correspondence and reprint requests to:
Haris S. Vasiliadis, Molecular Cell Biology and Regenerative
Medicine, Sahlgrenska University Hospital, Gothenburg University,
41345 Gothenburg, Sweden.
E-mail addresses: haris.vasiliadis@clinchem.gu.se, hvasil@cc.uoi.gr
